Evidence map›Paper›PMID 39021438›Full record

ArticleBrain, behavior, & immunity - health2024

Anti-spike antibody responses to SARS-CoV-2 mRNA vaccines in people with schizophrenia and schizoaffective disorder.

Katlyn Nemani, Livia De Picker, Faith Dickerson, Marion Leboyer, Michele Santacatterina, Fumika Ando, Gillian Capichioni, Thomas E Smith, Jamie Kammer, Kawtar El Abdellati and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain, behavior, & immunity - health, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Katlyn NemaniNathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.
Livia De PickerCollaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.
Faith DickersonDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Marion LeboyerInserm U955, Translational Psychiatry Laboratory, Université Paris-Est-Créteil, Department of Psychiatry and Addictology of Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Hôpital Albert Chenevier-Henri Mondor, Fondation FondaMental, Créteil, France.
Michele SantacatterinaDepartment of Population Health, New York University, New York, NY, USA.
Fumika AndoDepartment of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
Gillian CapichioniDepartment of Psychiatry, New York University Langone Medical Center, New York, NY, USA.
Thomas E SmithNew York State Office of Mental Health, New York, NY, USA.
Jamie KammerNew York State Office of Mental Health, New York, NY, USA.
Kawtar El AbdellatiCollaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.
Manuel MorrensCollaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.
Violette CoppensCollaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium.
Emily KatsafanasDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Andrea OrigoniDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Sabahat KhanDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Kelly RoweDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
R Sarah ZiemannDepartment of Psychology, Sheppard Pratt, Baltimore, MD, USA.
Ryad TamouzaInserm U955, Translational Psychiatry Laboratory, Université Paris-Est-Créteil, Department of Psychiatry and Addictology of Mondor University Hospital, Assistance Publique-Hôpitaux de Paris, Hôpital Albert Chenevier-Henri Mondor, Fondation FondaMental, Créteil, France.
Robert H YolkenThe Stanley Laboratory of Developmental Neurovirology, Johns Hopkins University, Baltimore, MD, USA.
Donald C GoffNathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Individuals with schizophrenia are at higher risk for severe COVID-19 illness and severe breakthrough infection following vaccination. It is unclear whether immune response to vaccination differs in this population. Objective: To assess whether anti-SARS-CoV-2 spike antibody titers after vaccination differ in people with a diagnosis of schizophrenia or schizoaffective disorder (SZ) compared to controls without a psychiatric disorder. Design: This cohort study assessed antibody response following the first and second dose of mRNA vaccines at longitudinal timepoints, up to 7 weeks following the first dose of vaccine. Setting: A multi-center study including psychiatric healthcare settings in the United States and Europe. Participants: 205 adults with no history of COVID-19 infection, including 106 individuals with SZ and 99 controls without a psychiatric disorder, who received their first dose of SARS-CoV-2 mRNA vaccine between December 20, 2020 and May 27, 2021. Main outcomes and measures: Mean SARS-CoV-2 anti-Spike IgG antibody levels within 7 weeks after the first dose of vaccination. Results: A total of 205 individuals (mean [SD] age, 44.7 [12.0] years; 90 [43.9%] male) were included, of which 106 (51.7%) were diagnosed with SZ. SZ was associated with lower mean log antibody levels (-0.15; 95% CI, -0.27 to -0.03, Conclusions and Relevance: In this cohort study of individuals with SZ and a control group without psychiatric disorders, SZ was associated with lower SARS-CoV-2 anti-spike antibody levels following 2 doses of SARS-CoV-2 mRNA vaccination. This highlights the need for further studies assessing vaccine immunogenicity in individuals with schizophrenia.

Indexed as

Antibody responseCOVID-19ImmunogenicitymRNA vaccineSchizoaffective disorderSchizophrenia

Identifiers

PMID39021438
PMCPMC11252076

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.